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Abstract
Background: The purpose of this study is to determine if low-dose aspirin improved ovarian
stimulation, endometrial response, or IVF pregnancy rates in our program.
Methods: Retrospective analysis of 316 consecutive IVF cycles from 1995 through 2001. Aspirin
80 mg daily was initiated at the start of luteal leuprolide in 72 cycles. The 244 controls received no
aspirin during treatment.
Results: The live birth rate in aspirin users was 29%, slightly lower compared to 41% in the no
aspirin control group (p = 0.07). Implantation rates were 21% with aspirin and 30% in the control
population (p = 0.01). There was no difference in the maximal endometrial thickness between
aspirin and non-aspirin groups. The two groups were similar regarding age, gonadotropin ampules,
embryos, number of embryos transferred, prior parity, diagnosis, use of intracytoplasmic sperm
injection, and stimulation protocol.
Conclusion: Low-dose aspirin was not beneficial to IVF patients in our program. Aspirin does not
enhance endometrial thickness, augment the ovarian response, or improve pregnancy rates.
Background
Numerous measures have been employed in an attempt
to increase implantation and pregnancy rates in assisted
reproduction. Aspirin has been utilized as one such
potential therapy. This drug has been shown to increase
uterine blood flow [1], hence clinicians have postulated
that aspirin could improve the receptiveness of the
endometrium, thereby increasing implantation and birth
rates.
Our institution at one time used aspirin routinely during
IVF cycles, based on the work of studies which showed
that low-dose aspirin increased implantation and preg-
nancy rates in women undergoing IVF [2,3]. Contrary data
from Urman and co-investigators found no improvement
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in IVF outcomes with low-dose aspirin [4]. Subsequently,
the use of aspirin was stopped in our program early in
2000. Since conflicting results have been reported in the
literature, we sought to compare pregnancy rates along
with other IVF outcome variables retrospectively in the
two groups of women (aspirin vs. non-aspirin) at our
institution.
Methods
This study was a retrospective analysis of 316 consecutive
IVF cycles from 1995 – 2001 at Carolinas Medical Center
comparing women who were treated with low-dose aspi-
rin versus those who did not receive aspirin treatment.
Aspirin was used in all initial cycles from 1995, and
excluded from most, but not all cycles beginning early in
2000 at the discretion of the attending physician. Demo-
graphic data including age, parity, cycle number, basal
FSH, diagnosis, method of stimulation, and use of intrac-
ytoplasmic sperm injection was obtained from our data-
base. For the purpose of this study, we divided method of
stimulation into GnRH antagonists, long luteal leupro-
lide, and micro-dose flare. The infertility diagnoses were
categorized into male factor, endometriosis, tubal factor,
ovulatory dysfunction, unexplained, and other, which
included uterine factors and immunological causes. The
pregnancy and delivery rates were stable in our program
from 1995 to 2001.
Seventy-two aspirin cycles were reviewed along with 244
non-aspirin cycles. For the aspirin cycles, 80 mg of aspirin
daily was initiated at the start of down-regulation with
luteal leuprolide. Aspirin was started on the first day of
leuprolide in microdose flare stimulations. Patients were
instructed to continue aspirin until they received the
results of their pregnancy tests. The controls received no
aspirin at any point during treatment. The outcome meas-
ures from the completed cycles were then reviewed. Of
interest were the number of gonadotropin ampules used,
endometrial thickness, number of eggs fertilized, number
of embryos transferred, implantation rate, pregnancy rate,
and live birth rate.
Statistics
The main independent variable was treatment with aspi-
rin (yes/no). Demographic and clinical characteristics for
each treatment group were reported and compared with
two-tailed t-test, Wilcoxon Rank Sum test, Chi-Square or
Fisher's Exact tests, as appropriate. The study outcomes
were analyzed in two stages: the first with Chi-Square tests
followed by a confirmatory analysis using a regression
method generalized estimating equations (GEE). Further
analysis of the outcomes assessed their association with
aspirin treatment after controlling for other patient and
clinical characteristics. The power of the study to deter-
mine a difference in pregnancy rates with and without
aspirin based on previous studies was approximately 60–
72% with an alpha of 0.05 [2,3].
Results and Discussion
There was no significant difference between age, previous
pregnancy, infertility diagnosis, prior IVF, basal FSH, and
method of stimulation between the aspirin and non-aspi-
rin groups. (Table 1) More women in the non-aspirin
group had been pregnant before (15.9% v. 9.7%) com-
pared to the aspirin group, but this did not achieve
statistical significance (p = 0.06).
Low-dose aspirin did not improve any IVF outcomes ana-
lyzed in this study, even though more embryos were trans-
ferred to women who used aspirin (p = 0.03) (Table 2). In
fact, the pregnancy rate in aspirin users was 48%, slightly
lower compared to non-users, 57% (p = 0.18). Clinical
pregnancy rates were 45% and 54% for users and non-
Table 1: Demographic Data
Aspirin No aspirin p
Number patients 72 (23%) 244 (77%)
Age 34 ± 4 34 ± 4 0.7
Previously pregnant 7 (10%) 39 (16%) 0.06
Diagnosis
• Unexplained 4 (6%) 12 (5%)
• Male factor 23 (32%) 51 (21%)
• Endometriosis 9 (13%) 51 (21%)
• Tubal factor 13 (18%) 54 (22%)
• Ovulatory dysfunction 12 (17%) 24 (10%)
• Other 6 (8%) 17 (7%)
• Multiple diagnoses 4 (6%) 54 (22%)
Prior IVF 32% 22% 0.12
Basal FSH (mIU/mL) 7 ± 2 7 ± 8 0.14
Stimulation method
• Antagonist 0 2 (1%)
• Long luteal leuprolide 62 (86%) 195 (80%)
• Flare 8 (11%) 34 (14%)
Table 2: Results
Aspirin No Aspirin P
Ampules (75 IU) 42 ± 15 44 ± 17 0.35
Endometrial thickness 12 ± 2 12 ± 2 0.26
ICSI 23 (32%) 67 (28%) 0.46
Oocytes fertilized 9 ± 4 9 ± 6 0.7
Embryos transferred 4 ± 1 3 ± 1 0.03
Pregnancy rate 48% 57% 0.18
Live birth rate 29% 41% 0.07
Implantation rate 21% 30% 0.01Journal of Experimental & Clinical Assisted Reproduction 2005, 2:8 http://www.jexpclinassistreprod.com/content/2/1/8
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users, respectively. Live birth rates tended to be lower with
aspirin, 29% and 41%, respectively (p = 0.07). Implanta-
tion rates were significantly lower in patients who
received aspirin, 21% and 30%, respectively (p = 0.01).
Maximal endometrial thickness was not improved with
aspirin compared to non-aspirin controls (p = 0.26). The
percentage of ICSI cycles was similar in each group, as was
the number of eggs fertilized.
Low-dose aspirin did not benefit IVF patients in our pro-
gram. Aspirin therapy did not enhance endometrial thick-
ness, augment the ovarian response, or improve
pregnancy rates. The demographics were similar between
the two groups of patients, with similarities in diagnosis,
stimulation protocol, as well as number of ICSI cycles.
Our results conflict with several studies that have shown
that aspirin is beneficial for infertility therapy. Rubenstein
et al found that aspirin 100 mg starting in the luteal phase
of the preceding cycle improved blood flow velocity, ovar-
ian responsiveness, implantation and pregnancy rates in a
randomized, controlled trial of 149 patients undergoing
IVF compared to 149 placebo-treated controls [2,5].
Weckstein et al also found enhanced uterine blood flow
and significantly higher implantation and clinical preg-
nancy rates with low-dose aspirin in women who had a
thin endometrium undergoing embryo transfer from
oocyte donation in a randomized controlled study [3].
Interestingly, endometrial thickness was not improved
with aspirin. In an prospective, randomized insemination
study of women with a thin endometrium undergoing
insemination, aspirin improved the percentage of trilami-
nar endometrium and pregnancy rates from 9 to 18%, but
not endometrial thickness or ultrasound flow patterns [6].
Waldenstrom et al randomized 1380 unselected IVF cycles
on alternate days to receive aspirin 75 mg or no aspirin
starting on the day of embryo transfer and continuing
until 18 days after retrieval [7]. In this study, the live birth
rate was 27% with aspirin and 23% in the control popu-
lation, with an odds ratio 1.2 (95% CI 1.0–1.6). A non-
controlled study found that IVF outcome was significantly
improved when aspirin, heparin, and intravenous immu-
noglobulin therapy was administered to women with
repeat IVF failures and antiphospholipid antibodies, but
not to women with negative antiphospholipid antibodies
[8]. Other studies have also found a beneficial effect with
aspirin/heparin, and aspirin plus prednisolone in IVF
patients [9-13]. In vitro studies have shown that aspirin
attenuates placental apoptosis, and this could be a possi-
ble explanation of how aspirin is beneficial, even in the
absence of endometrial or oocyte improvement [14]. Pro-
ponents of aspirin consider treatment to be a simple, inex-
pensive, and harmless means to improve IVF outcomes
[7].
However, some studies have shown anticoagulation ther-
apy to be ineffective, and sometimes detrimental, during
IVF. A large randomized controlled trial of low-dose aspi-
rin by Urman et al found no difference in implantation or
pregnancy rates in patients undergoing ICSI [4]. A higher
incidence of ectopic pregnancy was found in the aspirin
group. A prospective, randomized, placebo-controlled IVF
trial by Stern and colleagues found no benefit with aspirin
and heparin for women with prior IVF implantation fail-
ure and antiphospholipid or antinuclear antibodies [15].
Another small matched study of women undergoing fro-
zen embryo transfer found an 11% pregnancy rate with
aspirin compared to 33% in controls, although the results
were not statistically different [16]. Implantation rates
were also lower with aspirin therapy, 2.9%, compared to
10.9% in untreated patients in this study. An uncontrolled
study of IVF likewise found that outcomes were not
improved with aspirin and heparin compared to
conventional therapy [17]. Finally, a prospective, rand-
omized, double-blind, placebo-controlled trial of poor
responders by Lok et al found no benefit with daily aspi-
rin 80 mg for cancellation rates, total dose of hMG used,
number of mature follicles, or number of oocytes
retrieved [18]. Furthermore, there was no difference in
intraovarian or uterine artery pulsatility index with daily
aspirin.
Randomized controlled trials have repeatedly shown that
combined aspirin plus heparin improves pregnancy out-
comes for women with recurrent pregnancy losses attrib-
uted to antiphospholipid antibodies [19,20]. This benefit
is also shown in a prospective series [21]. Outcomes are
better with aspirin plus heparin therapy than with aspirin
alone in most [20,21], but not all studies [22,23]. Aspirin
plus corticosteroid therapy, on the other hand, may be
harmful. Combined low-dose aspirin plus prednisone
increased the risk of preterm birth in two randomized
controlled trials [24,25]. With a minimal benefit of aspi-
rin alone for women with recurrent pregnancy losses and
antiphospholipid antibodies, it is not surprising that we
failed to find a beneficial effect of aspirin therapy in our
general IVF population.
In our study, we did not test for uterine blood flow or rou-
tinely test for antiphospholipid antibodies. Therefore, we
were not able to sub-divide the women in our study into
groups that might be more responsive to aspirin. How-
ever, an ASRM Practice Committee Report in 1999 con-
cluded that antiphospholipid antibodies do not affect IVF
success, and therapy is not justified [26]. Furthermore, we
believe that implantation rates, pregnancy rates, and live
birth rates are more important indicators of IVF outcomeJournal of Experimental & Clinical Assisted Reproduction 2005, 2:8 http://www.jexpclinassistreprod.com/content/2/1/8
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compared to indirect measurements such as endometrial
blood flow. In our study, pregnancy, implantation, and
live birth rates were higher in the non-aspirin control
group.
Another weakness in our study is the six-year period over
which our IVF cycles were reviewed. It is possible that sub-
tle differences could bias results in the aspirin and control
groups in a retrospective analysis. Additionally, the small
study population yields a limited statistical power to
detect minor differences in pregnancy outcomes with
aspirin. There are actual and sometimes large differences
between the two groups of women, which could affect the
outcomes. The differencesare not significant, but might be
due to the small population studied. There certainly could
be minor changes in treatment protocols over that span of
time, but our age-related pregnancy and live birth rates
remained stable during the years of this study.
Based on the results from our study and the prospective
randomized trials by Urman and colleagues [4] and Stern
et al [15], aspirin is not beneficial for a general IVF popu-
lation. Since implantation, pregnancy, and delivery rates
are higher for non-aspirin users, our study raises the pos-
sibility that aspirin may lower IVF success. A potential fer-
tility reducing effect of aspirin is plausible, since
prostaglandins affect ovulation, fertilization, and implan-
tation [27]. Since aspirin inhibits prostaglandin synthesis,
implantation could be compromised. Clearly, a larger,
prospective randomized study with adequate power
would be needed to determine if low-dose aspirin reduced
IVF success.
There is some risk associated with aspirin therapy for
infertility, although the extent of the risk for a healthy
infertility population is unclear. One population based
cohort study found that aspirin and nonsteroidal anti-
inflammatory agents increased the risk of miscarriage,
although a recent meta-analysis showed no increased risk
of miscarriage with aspirin [28,29]. Although aspirin does
not appear to alter the risk of congenital anomalies, first
trimester aspirin consumption may increase the incidence
of gastroschisis [30]. Acetylsalicylic acid may reach the
uteroplacental circulation and exert antiplatelet effects in
the fetus and newborn, although the incidence of neona-
tal bleeding does not appear to be increased with mater-
nal aspirin [31,32]. However, maternal aspirin may raise
the risk of placental abruption and antenatal, intrapar-
tum, and postpartum hemorrhage [32,33]. Additionally,
there is at least one reported maternal death due to com-
plications of cerebral hemorrhage in a woman treated
with aspirin and heparin after IVF [34]. Although these
risks may be small, treatment with aspirin is not justified
in the absence of a proven benefit.
Conclusion
Low-dose aspirin did not enhance endometrial thickness,
augment the ovarian response, or improve pregnancy
rates in our study. There is no apparent benefit in the rou-
tine use of aspirin during IVF cycles, and this practice
should be abandoned.
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